BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 32204955)

  • 1. Targeting MCL-1 in hematologic malignancies: Rationale and progress.
    Wei AH; Roberts AW; Spencer A; Rosenberg AS; Siegel D; Walter RB; Caenepeel S; Hughes P; McIver Z; Mezzi K; Morrow PK; Stein A
    Blood Rev; 2020 Nov; 44():100672. PubMed ID: 32204955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia.
    Tron AE; Belmonte MA; Adam A; Aquila BM; Boise LH; Chiarparin E; Cidado J; Embrey KJ; Gangl E; Gibbons FD; Gregory GP; Hargreaves D; Hendricks JA; Johannes JW; Johnstone RW; Kazmirski SL; Kettle JG; Lamb ML; Matulis SM; Nooka AK; Packer MJ; Peng B; Rawlins PB; Robbins DW; Schuller AG; Su N; Yang W; Ye Q; Zheng X; Secrist JP; Clark EA; Wilson DM; Fawell SE; Hird AW
    Nat Commun; 2018 Dec; 9(1):5341. PubMed ID: 30559424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
    Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
    Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting.
    Slomp A; Moesbergen LM; Gong JN; Cuenca M; von dem Borne PA; Sonneveld P; Huang DCS; Minnema MC; Peperzak V
    Blood Adv; 2019 Dec; 3(24):4202-4214. PubMed ID: 31856269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents.
    Bolomsky A; Vogler M; Köse MC; Heckman CA; Ehx G; Ludwig H; Caers J
    J Hematol Oncol; 2020 Dec; 13(1):173. PubMed ID: 33308268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML.
    Ewald L; Dittmann J; Vogler M; Fulda S
    Cell Death Dis; 2019 Dec; 10(12):917. PubMed ID: 31801941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.
    Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N
    Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
    Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
    Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-Myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia.
    Liu S; Qiao X; Wu S; Gai Y; Su Y; Edwards H; Wang Y; Lin H; Taub JW; Wang G; Ge Y
    Apoptosis; 2022 Dec; 27(11-12):913-928. PubMed ID: 35943677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCL2 and MCL1 inhibitors for hematologic malignancies.
    Roberts AW; Wei AH; Huang DCS
    Blood; 2021 Sep; 138(13):1120-1136. PubMed ID: 34320168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells.
    Doi K; Gowda K; Liu Q; Lin JM; Sung SS; Dower C; Claxton D; Loughran TP; Amin S; Wang HG
    Cancer Biol Ther; 2014; 15(12):1688-99. PubMed ID: 25535900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
    Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
    Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition.
    Carter BZ; Mak PY; Tao W; Warmoes M; Lorenzi PL; Mak D; Ruvolo V; Tan L; Cidado J; Drew L; Andreeff M
    Haematologica; 2022 Jan; 107(1):58-76. PubMed ID: 33353284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Bcl-2 for the treatment of multiple myeloma.
    Touzeau C; Maciag P; Amiot M; Moreau P
    Leukemia; 2018 Sep; 32(9):1899-1907. PubMed ID: 30076373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maritoclax induces apoptosis in acute myeloid leukemia cells with elevated Mcl-1 expression.
    Doi K; Liu Q; Gowda K; Barth BM; Claxton D; Amin S; Loughran TP; Wang HG
    Cancer Biol Ther; 2014 Aug; 15(8):1077-86. PubMed ID: 24842334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemokine receptor CXCR4: An important player affecting the molecular-targeted drugs commonly used in hematological malignancies.
    Li L; Chai Y; Wu C; Zhao L
    Expert Rev Hematol; 2020 Dec; 13(12):1387-1396. PubMed ID: 33170753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rise of apoptosis: targeting apoptosis in hematologic malignancies.
    Valentin R; Grabow S; Davids MS
    Blood; 2018 Sep; 132(12):1248-1264. PubMed ID: 30012635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutics targeting Bcl-2 in hematological malignancies.
    Ruefli-Brasse A; Reed JC
    Biochem J; 2017 Oct; 474(21):3643-3657. PubMed ID: 29061914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloid cell leukemia 1 (MCL-1): Structural characteristics and application in cancer therapy.
    Mittal P; Singh S; Sinha R; Shrivastava A; Singh A; Singh IK
    Int J Biol Macromol; 2021 Sep; 187():999-1018. PubMed ID: 34339789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors.
    Juarez D; Buono R; Matulis SM; Gupta VA; Duong M; Yudiono J; Paul M; Mallya S; Diep G; Hsin P; Lu A; Suh SM; Dong VM; Roberts AW; Leverson JD; Jalaluddin M; Liu Z; Bueno OF; Boise LH; Fruman DA
    Cancer Res Commun; 2023 Dec; 3(12):2497-2509. PubMed ID: 37956312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.